Atyr Pharma Inc
ATYR
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.55B
Close$
$-0.02
104.5% downside
Current Fair Value
104.5% downsideOvervalued by 104.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.55 Billion |
|---|---|
| Enterprise Value | $2.55 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.8 |
| Beta | 0.53 |
| Outstanding Shares | 98,069,915 |
Return
| Return on Equity | -124.64% |
|---|---|
| Return on Assets | -87.08% |
| Return on Invested Capital | -109.29% |
Valuation & Multiples
| P/E Ratio | -0.69 |
|---|---|
| PEG | 1.47 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 13419.76 |
| Enterprise Value to EBIT | -39.93 |
| Enterprise Value to Net Income | -42 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
$2.50 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Atyr Pharma Inc
80 employees
CEO: Sanjay Shukla atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological ...